Prefilled Syringe Small Molecule Market (Therapeutic Class - Neurology Drug, Cardiovascular Drugs, Analgesics, and Adjuvants) - U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Albany, NY -- (SBWIRE) -- 12/07/2016 -- According to the report, U.S. and EU-5 Prefilled Syringes Small Molecule Market was valued at US$ 9.15 Bn in 2015 and is projected to expand at a CAGR of 7.8% from 2016 to 2024 to reach US$ 17.1 Bn in 2024. This report offers a thorough understanding of prefilled syringes small molecule market in the U.S. and EU5, its key trends, drivers, restraints, and opportunities.
Established pharmaceutical companies as well as companies vying to enter the prefilled syringes small molecule market in EU5 and the U.S. can expect the neurology small molecule drug and cardiovascular small molecule drug prefilled syringe segments to experience high growth and generate substantial revenue during the forecast period. Neurology small molecule drugs in prefilled syringes contain glatiramer acetate. Growth of the neurology and cardiovascular small molecule drug prefilled syringe segment is attributed to need for availability in rising emergency situations and safety and ease of drug dose delivery in EU5 and the U.S. Prominent prefilled syringe brands already having popular presence in cardiovascular small molecule drug segments include Epipen (Mylan N.V.), Anapen (Bioprojet Pharma), and Fastjekt (Meda Pharmaceutical Inc. now part of Mylan N.V.). Due to recent legislative issues regarding the pricing hikes in US for Epipen; however, Mylan N.V. has expected a drop in sales and devised a product portfolio extension strategy to overcome the anticipated fall in revenues by introducing a generic equivalent to the Original Epipen brand. Additionally, other players in cardiovascular small molecule drug prefilled syringe market are seeking to grab this opportunity. In neurology small molecule drug segment has only one small molecule in prefilled syringe and there was only one brand by name Copaxone (Sanofi has rights for US, Teva pharmaceutical industries has rights for EU5), Recently Sandoz has introduced its prefilled syringe brand Glatopa containing glatiramer acetate. The neurology small molecule drug prefilled syringe segment is highest revenue earning among other small molecules. The launch of Glatopa will attract the other players to introduce their offerings in this segment. Competition in the prefilled syringes small molecule market has intensified due to the increased entry of local players and increasing foray of generic equivalents. However, biological in prefilled syringes are anticipated to be an emerging and upcoming market, especially for a niche segment. But high capital investment required and product stability issues will have a limited players in market at the beginning.
Get Exclusive Sample Copy of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16988
In UE5, growth in metabolic diseases and change in lifestyle leading to lifestyle diseases together owing to rising emergency neurological and cardiovascular conditions has led to sharp increase in demand for prefilled syringes in the past few years. Also small molecule drugs coming off patents and rising foray of generic equivalents are likely to drive the prefilled syringe small molecule market in EU5 during the forecast period. Adjuvant's segment in prefilled syringes small molecule market is expected to have steady growth over forecasted period. Abundant availability of raw material, increasing demand for safety and ease of drug delivery, and presence of many small and big players are the factor anticipated to expand the adjuvants prefilled syringe small molecule market in US and EU5. The analgesic small molecule drug prefilled syringe market is also expected to have a steady growth in US and EU5 over the forecasted period owing to the rising number of interventional procedures, need for safety and accuracy of dose delivery. However, poor product quality and inaccurate dosage in prefilled syringes have put many players in US to recall their products from market especially in US market.
Major companies competing in the prefilled syringe small molecule market, and profiled in the report include Teva Pharmaceutical Industries Ltd., Hospira, Inc (Now Pfizer, Inc.), Mylan N.V., Fresenius Kabi, Becton, Dickinson and Company and Sanofi .